Skip to main content

Table 1 Patient characteristics (n = 25)

From: Case series of cancer patients who developed cholecystitis related to immune checkpoint inhibitor treatment

Characteristic

Value

Age, years, mean (SD)

60 (11)

Male, n (%)

15 (60)

Race/ethnicity, n (%)

 White

16 (64)

 Hispanic

5 (20)

 Other

4 (16)

Ever smoker, n (%)

12 (48)

Comorbidities, n (%)

 Diabetes mellitus type 2

6 (24)

 Hypertension

18 (72)

 Hyperlipidemia

11 (44)

 Ischemic heart disease

5 (20)

Body mass index, kg/mm2, mean (SD)

28 (5)

Cancer type, n (%)

 Genitourinary cancer

9 (36)

 Hematologic cancer

5 (20)

 Melanoma

4 (16)

 Gastrointestinal cancer

4 (16)

 Other

3 (12)

Cancer stage, n (%)a

 III

4 (16)

 IV

16 (64)

ICI type, n (%)

 Anti–CTLA-4

8 (32)

 Anti–PD-1/L1

15 (60)

 Combination

2 (8)

ICI given with chemotherapy known to cause gallbladder disease, n (%)

4 (16)

Other irAEs, n (%)

 Skin

4 (16)

 Lungs

3 (12)

 Endocrine

3 (12)

 Colitis

1 (4)

 Hepatitis

1 (4)

 Other

2 (8)

  1. aAvailable for 20 patients with solid tumors. SD standard deviation, ICI immune checkpoint inhibitor, CTLA-4 cytotoxic T-lymphocyte associated antigen 4, PD-1/L1 programmed cell death protein 1 or its ligand, irAE immune-related adverse event